The nondigestible oligosaccharides (NDOs) are typically saccharides containing between 3 and 10 sugar moieties, including isomalt-oligosaccharides (IMOs), galacto-oligosaccharides (GOSs), XOSs, and some pseudo-oligosaccharides, such as acarbose (38, 46)
No Pediatric Research Equity Act (PREA) requirement has compelled Novo Nordisk to conduct trials in children aged 6 to 11 for this specific indication, though the company's ClinicalTrials.gov profile lists ongoing pediatric pharmacokinetic studies for semaglutide in younger populations
Your provider may adjust pace based on side effects and biomarker changes
doi: 10.1007/s40618-015-0404-6 29 HabibZAHavstadSLWellsKDivineGPladevallMWilliamsLK
And so that suggests that theres some overlapping pathways there
Oral drugs do away with several of the drawbacks that are associated with injectable drugs, such as needle fear and difficulties with administration